The skin of a patient is the first and most visible structure of the body that any health-care worker encounters during the course of an examination. To the patient, it is also highly visible, and a
...
ny disease that affects it is noticeable and will have an impact on personal and social well-being. The skin is therefore an important entry point for both diagnosis and management. Many diseases of humans are associated with changes to the skin, ranging from symptoms such as itching to changes in colour, feel and appearance.
This training guide explains how to identify the signs and symptoms of neglected tropical diseases of the skin through their visible characteristics. It also contains information on how to diagnose and manage common skin problems that front-line health workers may encounter.
more
In order to maintain daily operations and patient care services, health care facilities need to develop an Emergency Water Supply Plan (EWSP) to prepare for, respond to, and recover from a total or partial interruption of the facilities’ normal wa
...
ter supply. Water supply interruption can be caused by several types of events such as natural disaster, a failure of the community water system, construction damage or even an act of terrorism.
The planning guide provides a four step process for the development of an EWSP:
1. Assemble the appropriate EWSP Team and the necessary background documents for your facility;
2. Understand your water usage by performing a water use audit;
3. Analyze your emergency water supply alternatives; and
4. Develop and exercise your EWSP
more
Prepared as an outcome of ICMR Subcommittee on Breast Cancer |.This consensus document on management of breast cancers summarizes the
modalities of treatment including the site-specific anti-cancer therapies, supportive and palliative care and mole
...
cular markers and research questions. It also interweaves clinical, biochemical and epidemiological studies.
more
Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection
July 2019
Policy brief
HIV Treatment
Technical Update
HIV Treatment
July 2017
Although 10% of the population in the U.S. reports a penicillin allergy, less than 1% of the population is truly penicillin allergic. Correctly identifying if your patient is penicillin allergic can decrease the unnecessary use of broad spectrum ant
...
ibiotics.
more
This document simplifies the WHO guidance on severe acute respiratory infection (SARI) treatment centres and is meant to be accessible to healthcare workers, policymakers and others who want
a quick overview of the key requirements for a COVID-19 i
...
solation centre either within an existing facility or as a standalone centre.
more
An Evidence-Based Treatment Guide for Clinicians
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Sleeping sickness is controlled by case detection and treatment but this often only reaches less than 75% of the population. Vector control is capable of completely interrupting HAT transmission but is not used because of expense. We conducted a ful
...
l scale field trial of a refined vector control technology. From preliminary trials we determined the number of insecticidal tiny targets required to control tsetse populations by more than 90%. We then carried out a full scale, 500 km2 field trial covering two HAT foci in Northern Uganda (overall target density 5.7/km2). In 12 months tsetse populations declined by more than 90%. A mathematical model suggested that a 72% reduction in tsetse population is required to stop transmission in those settings. The Ugandan census suggests population density in the HAT foci is approximately 500 per km2. The estimated cost for a single round of active case detection (excluding treatment), covering 80% of the population, is US$433,333 (WHO figures). One year of vector control organised within country, which can completely stop HAT transmission, would cost US$42,700. The case for adding this new method of vector control to case detection and treatment is strong. We outline how such a component could be organised.
more
Overview
Learning objectives
• Understand the mental health treatment gap in low-, middle- and high-income countries.
• Understand the principles and aims of the Mental Health Gap Action Programme.
• Acquire an introduction to mhGAP Interv
...
ention Guide (mhGAP-IG).
• Learn about mhGAP ToHP training methodology and what to expect from mhGAP ToHP
training.
• Prepare group training ground rules.
• Know the common presentations of mental, neurological and substance abuse (MNS)
conditions.
more
The health system in Venezuela: a patient without medication?
Cad. Saúde Pública 34 (3) 05 Mar 2018 • https://doi.org/10.1590/0102-311X00058517
Barriers to the prompt and effective diagnosis and treatment of malaria exist at both the community and health facility level. Household surveys measure malaria case management at the population level with standard indicators that assess
...
treatment-seeking behavior, access to diagnostic testing, and access to appropriate treatment. Performance on these indicators varies widely from country to country. Among countries with Demographic and Health Surveys (DHS) or Malaria Indicator Surveys (MIS) completed between 2014 and 2016, advice and treatment was sought for a median of 47% of children under age 5 with fever.
more
Evaluating the Return on Investment of Scaling Up Treatment for Depression, Anxiety, and Psychosis
2018
9th Edition
Offering information on HIV/AIDS treatment, prevention, and research
Solidarity” is an international clinical trial to help find an effective treatment for COVID-19, launched by the World Health Organization and partners.
The Solidarity Trial will compare four treatmen
...
t options against standard of care, to assess their relative effectiveness against COVID-19. By enrolling patients in multiple countries, the Solidarity Trial aims to rapidly discover whether any of the drugs slow disease progression or improve survival. Other drugs can be added based on emerging evidence.
Until there is sufficient evidence, WHO cautions against physicians and medical associations recommending or administering these unproven treatments to patients with COVID-19 or people self-medicating with them. WHO is concerned by reports of individuals self-medicating with chloroquine and causing themselves serious harm.
more
إرشاداتٌ حول إنشاء عنابر العزل الخاصة بالحالات المصابة بفيروس كورونا المستجد
This document simplifies the WHO guidance on severe acute respiratory infection (SARI) treatment centr
...
es and is meant to be accessible to healthcare workers, policymakers and others who want
a quick overview of the key requirements for a COVID-19 isolation centre either within an existing facility or as a standalone centre.
more
WHO published guidance for clinicians and health care decision-makers on the use of corticosteroids in patients with COVID-19.
We recommend systemic corticosteroids for the treatment of patients with severe and critical COVID-19. We suggest not t
...
o use corticosteroids in the treatment of patients with non-severe COVID-19 as the treatment brought no benefits, and could even prove harmful. Treatment should be under supervision of a clinician.
Corticosteroids are listed in the WHO model list of essential medicines, readily available globally at a low cost. WHO encourages countries to maintain sufficient stocks of corticosteroids to treat COVID-19 and the other disease for which they are effective, while not maintaining excessive stocks which could deny other countries access.
more
How to do it best for the patient and the family